Compare · NUWE vs TMDX
NUWE vs TMDX
Side-by-side comparison of Nuwellis Inc. (NUWE) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NUWE and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $2.57B, about 6708.9x NUWE ($382,706).
- Over the past year, NUWE is down 98.5% and TMDX is down 47.2% - TMDX leads by 51.3 points.
- TMDX has been more active in the news (12 items in the past 4 weeks vs 10 for NUWE).
- TMDX has more recent analyst coverage (18 ratings vs 1 for NUWE).
- Company
- Nuwellis Inc.
- TransMedics Group Inc.
- Price
- $0.14-1.23%
- $74.36+4.47%
- Market cap
- $382,706
- $2.57B
- 1M return
- -87.03%
- +9.69%
- 1Y return
- -98.53%
- -47.21%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 10
- 12
- Recent ratings
- 1
- 18
Nuwellis Inc.
Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Brunei, Germany, Greece, Hong Kong, India, Israel, Italy, Palestine, Singapore, Spain, Switzerland, Thailand, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest NUWE
- Nuwellis Announces Closing of $6.0 Million Registered Public Offering
- SEC Form 424B4 filed by Nuwellis Inc.
- Nuwellis Announces Pricing of $6 Million Public Offering
- SEC Form S-1MEF filed by Nuwellis Inc.
- SEC Form EFFECT filed by Nuwellis Inc.
- Amendment: SEC Form S-1/A filed by Nuwellis Inc.
- SEC Form FWP filed by Nuwellis Inc.
- Amendment: SEC Form S-1/A filed by Nuwellis Inc.
- SEC Form SD filed by Nuwellis Inc.
- SEC Form S-1 filed by Nuwellis Inc.
Latest TMDX
- SEC Form SD filed by TransMedics Group Inc.
- Director Basile Edward M was granted 2,922 shares, increasing direct ownership by 102% to 5,788 units (SEC Form 4)
- Director Gunderson Thomas J. was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)
- Director Raines Merilee was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)
- Director Weill David was granted 2,922 shares, increasing direct ownership by 24% to 15,056 units (SEC Form 4)
- Director Lovell Stephanie was granted 2,922 shares, increasing direct ownership by 102% to 5,788 units (SEC Form 4)
- Director Tobin James R was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)
- Director Kania Edwin was granted 2,922 shares, increasing direct ownership by 1% to 263,732 units (SEC Form 4)
- Officer Forsyth Matthew S. was granted 15,409 shares (SEC Form 4)
- SEC Form 8-K filed by TransMedics Group Inc.